To apply for BioGenerator Spark funding complete our non-confidential Application Form. BioGenerator is willing to enter into a confidentiality agreement at the Application stage. If an agreement is in place, the application can include confidential information. Contact BioGenerator prior to completing the application if you have any questions about protecting your intellectual property or the steps necessary to allow BioGenerator to receive confidential information. Key components of the application include:

• Scientific and technical background and plans and associated budget
• Business development strategy - funding, market, differentiation, etc.

BioGenerator staff review all Spark Fund submissions. Because staff time and funding are not unlimited, prior to to conducting formal Due Diligence, at the first stage of triage our team looks for:

• Likelihood of success
• Overall fit with BioGenerator mission
• Any critical gaps that do not allow funding

At the completion of the first level review, technologies will either proceed to the next stage or applicants will receive a decision letter providing key factors in BioGenerator's decision not to provide funding. Applicants may re-apply for Spark funding at any time.

Our staff works with the applicant in an iterative process to assess and develop the concept to the point where BioGenerator is confident that milestones reached during the pre-seed funding period will enable the company to become successful, either by raising additional funding or reaching the point of self-sufficiency. In the earliest stages of technology commercialization, this process is highly unique to each opportunity. In some cases, Spark applications rapidly move toward deal closing, while in others there is significant business development necessary. It is also possible to reach a no go decision based on new information identified in diligence, or because a suitable management or technical team cannot be assembled.

At the conclusion of the Development and Due Diligence process, applications are reviewed by the BioGenerator team. For successful applicants, an Investment Offer is prepared. Applications that aren't approved for funding by the BioGenerator staff will receive a decision letter providing key factors in BioGenerator's decision not to provide funding.

Commercialization concepts approved by the BioGenerator Team will receive an Investment Offer. The BioGenerator Spark Fund program has defined investment terms and supporting documents for technology, service and product-based investments. Spark Fund investments may be syndicated with other pre-seed investors or BioGenerator may be the only investor. In all Spark Fund investments, BioGenerator requires that its investment documents are used for Deal Closing.

A typical Deal Closing for a BioGenerator Spark Fund investment requires the following documents to be executed:

• Note Purchase Agreement (multi-party deal)
• Convertible Promissory Note

At the conclusion of Deal Closing, funds are transferred electronically to the company's bank account.

BioGenerator typically continues to provide support through the investment period and beyond. BioGenerator gives input on the progress of the company towards the agreed upon milestones and works to connect the company with additional and downstream investors.